April 20, 2024
Bio
GC Pharma initiates patient dosing for anti-EGFR therapy
[THE INVESTOR] GC Pharma said on April 5 that the first patient was dosed in its phase 1b/2a clinical trials of cancer drug candidate GC1118.
GC1118, an anti-epidermal growth factor receptor monoclonal antibody, is being jointly developed by the Korean drug maker and Mogam Biotechnology Institute.
 |
The phase 1b study is designed to predict the dosage range of GC1118 in combination with other chemotherapy treatments Irinotecan or FOLFIRI in patients with recurrent and metastatic colorectal cancer. The safety and efficacy of the drug will be evaluated in phase 2a trials.
“We plan to expand indications to gastric cancer depending on the early clinical trial results,” a GC Pharma official told The Investor.
By Park Han-na (hnpark@heraldcorp.com)
